Ovulation rate (OR) and litter size (LS) were recorded in a flock of Cambridge sheep from 1984 to 1994 and from 1976 to 1994 respectively. There were 1516 and 2480 OR and LS records with means of 3·2 and 2·5 respectively. There was considerable variation in results between years ranging from 2·2 to 3·2 for LS and from 2·8 to 4·2 for OR. Ewe lamb OR was affected by year of recording, some years having higher OR than others. Rearing type (single, twin or triplet) also affected ewe lamb OR, twins having lower OR than both singles and triplets. Ewe lamb OR decreased with later date of birth reflecting a lower age at OR counting. Ewe lamb LS was affected by year of recording and there was also an interaction between date of birth and year indicating that OR decreased with later date of birth in some years but not in others. OR of adult ewes was affected by year of recording which also interacted with age (2, 3 and 4). Generally, OR increased with age but this trend was not observed in all years. LS of adult ewes was significantly affected by year and increased with ewe age (2, 3 and 4). Heritability and repeatability were determined for ewe lamb OR and LS and adult ewe OR and LS in univariate and two-trait analyses using DFREML. Heritabilities of ewe lamb OR (0·18 to 0·21) and LS (0·05 to 0·08) were lower than corresponding adult ewe values for OR (0·19 to 0·34) and LS (0·19 to 0·22). Ewe OR had a lower repeatability (0·43 to 0·55) than LS (0·30 to 0·80). High genetic correlations (>0·9) were obtained for combinations of ewe lamb OR, ewe lamb LS, adult ewe OR and adult ewe LS. The importance of analysing ewe lamb and ewe records separately is discussed as is the value of ewe lamb OR as a selection criterion.
Objective. Ectopic pregnancy adversely affects the patency of the fallopian tube and consequently the future pregnancy. There are different options of conservative treatment of tubal pregnancy such as methotrexate and salpingostomy [1]. There is little information on the success rate of maintaining tubal patency after methotrexate and salpingostomy [2]. Therefore, the aim of this study is to evaluate the ipsilateral tubal patency using HyCoSy after treatment of tubal pregnancy with methotrexate therapy versus salpingostomy. Patients and methods. This was a case-series study conducted in Ain Shams and Al-Azhar University Maternity Hospitals to evaluate the ipsilateral tubal patency using hysterosalpingo-contrast sonography (HyC0Sy) following salpingostomy and medical treatment of tubal pregnancy. This study included patients who were admitted to Ain Shams and Al-Azhar University Maternity Hospitals for having tubal pregnancy and were treated either with methotrexate or salpingostomy over a 4-year period between January 2017 and December 2020. The patients seeking fertility were re-evaluated for fallopian tubes patency by hysterosalpingogram 3 months after discharge. The study included 2 groups of women: group I (n = 200): women who were treated with methotrexate, and group II (n = 140): women who underwent salpingostomy. Results. HSG was performed in 200 cases of patients with tubal pregnancy who were treated with methotrexate and 140 cases of patients who underwent salpingostomy. The patency of the ipsilateral tube was 85% after methotrexate treatment and 84.2% after salpingostomy. There was no statistically significant difference between the two groups. Conclusion. The findings suggest similar success rate in maintaining the patency of the fallopian tube with either methotrexate or salpingostomy. Key words: ectopic pregnancy, hysterosalpingography, methotrexate, infertility, salpingostomy
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.